LataMed AI Corp. (OTC: LMED) announced today that it expects to submit a corporate action request to FINRA seeking approval of a five-for-one forward stock split, along with proportional increases in authorized common and preferred stock. The move is intended to support the company's operational scalability and strategic flexibility as it expands its telehealth infrastructure and healthcare analytics platforms in emerging markets, with an initial focus on Latin America.
The proposed forward stock split would apply proportionally to all issued and outstanding shares of common stock and preferred stock, including the Series C Voting Preferred Stock. The company emphasized that the action does not involve debt restructuring, recapitalization, or any reduction in shareholder ownership percentages. No fractional shares are expected to be issued, as any fractional interests would be rounded up to the nearest whole share.
Management stated that the forward stock split is part of a broader effort to align the company's capital structure with its transition into digital healthcare and AI-driven telehealth operations. Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI, said: “As we continue advancing our operational and commercialization initiatives throughout Latin America, we believe this proposed forward stock split and proportional capital structure expansion may support broader long-term strategic flexibility, operational scalability, and future growth initiatives as we continue building our healthcare technology platform.”
The company recently commenced initial operational activities for its telehealth platform in Venezuela after receiving regulatory authorization from the Ministerio del Poder Popular para la Salud and Servicio Autonomo de Contraloria Sanitaria (SACS). This regulatory progression is a key milestone in LataMed's strategy to deploy digital health solutions in underserved markets.
The proposed forward stock split remains subject to FINRA review and approval, as well as completion of applicable regulatory processing and final corporate implementation procedures. No assurance can be provided regarding the timing or ultimate effectiveness of the proposed action.
LataMed AI Corp. is a development-stage digital health and artificial intelligence technology company focused on telehealth infrastructure and healthcare analytics for emerging markets. The company has not yet generated revenues from its current business operations but is advancing a technology-enabled healthcare ecosystem designed to support remote patient engagement, provider coordination, and broader digital healthcare delivery.
For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
